INTRODUCTION
e goal of medical treatment in patients with Crohn's disease (CD) has shi ed from symptom c ont rol a l one to cl i n i c a l remission in conjunction with mucosal healing [1] . is latter point seems to be particularly important, because reaching this goal would also produce a domino e ect, resulting in fewer complications, hospitalization, and related surgical procedures [2, 3] . is is particularly true when considering the therapeutic use of biologic therapies. The pro-inflammatory cytokine Tumour Necrosis Factor-alpha (TNF-α) appears to play a pivotal role in the pathogenesis of mucosal in ammation, mediating the in ammatory cascade in CD [3] . TNF-α is mainly produced by monocytes and macrophages, although many other cells of the innate and adaptive immune system produce signi cant amounts of this cytokine [4] . Anti-TNFα therapy by using In iximab (IFX) or Adalimumab (ADA) can lead to endoscopically assessed mucosal healing in patients with CD, avoiding surgery and maintaining a steroid-free remission up to 12 months [5] .
Adhesion molecules containing heparan sulphate (syndecan family) are chemically proteo-glycans and play a signi cant role in tissue repair [6] . At the intestinal level, syndecan 1 (SD1) is located in the basolateral region of the columnar epithelium and is a relevant factor for damage reversal in in ammatory bowel disease [7] . In particular, it has been shown that SD1 is signi cantly decreased in mucosa and increased in serum of active CD, and seems to be able to di erentiate between CD and J Gastrointestin Liver Dis, September 2014 Vol. 23 No 3: 261-265 other granulomatous intestinal diseases, such as tuberculosis [8] . Moreover, basic fibroblast growth factor (bFGF) is a peptide able to repair ulcerative lesions, thanks to its capacity to bind epithelial and stromal cells [9] . It has been suggested that SD1 promotes bFGF morphology changes and modulates the structure of its receptors [10] . During the physiological restoration of mucosa in in ammatory bowel disease, SD1 migrates from basolateral epithelium to both epithelial apical surface and stroma and modulates bFGF activity. In detail, such a phenomenon favours the binding between bFGF and those cells dedicated to the repair process, which are located next to an ulcerative lesion. When it is not activated by SD1, bFGF may be destroyed by both luminal and circulating proteases, thus failing its role in the tissue restoration [11] .
e induction of collagen secretion from broblasts by bFGF may be one of the mechanisms relevant to the stromal process disease in in ammatory bowel disease, in particular in CD, including transmural brosis and stricture formation, as well as tissue repair and healing [12] . TNF-α down-regulation presumably interacts with the adhesion molecules such as SD1 [3] and growth factors such as bFGF [4] in the process of mucosal repair. Indeed, SD1 is located in the basolateral region of the columnar epithelium and plays a relevant role in the course of in ammatory bowel disease damage reversal [5, 13] .
It has been showed that CD, especially stenosing CD, shows impaired relation among this cytokine/adhesion molecule/ growth teamwork factor. is "pro-brosis" behavior could explain the tendency toward fibrosis in CD [14] . On the contrary, we do not know what the behaviour of this teamwork factor is in CD in deep remission under treatment with anti-TNFα antibodies. Moreover, we do not know whether a di erent relationship among the cytokine/adhesion molecule/ growth teamwork factor in patients taking IFX from those taking ADA is detectable.
We aimed to assess the mucosal expression of this molecular framework in CD patients in deep remission with IFX or ADA, compared with a control group of patients with active CD.
MATERIAL AND METHODS
This was a retrospective, observational, multicentre study, performed on patients with CD in clinical, laboratory and endoscopic remission and undergoing surveillance colonoscopy while receiving maintenance therapy with IFX or ADA.
Patients under treatment with IFX or ADA with a con rmed history of CD and under sustained deep remission were enrolled. All patients were under scheduled treatment with IFX 5 mg/kg/i.v. every 8 weeks or ADA 40 mg subcutaneously every other week in order to maintain remission. No patient received mesalamine enemas, corticosteroids, or immunosuppressants (tacrolimus, azathioprine, and 6-mercaptopurine) during the study period. According to our standard procedure, immunosuppressants were started at the beginning of the IFX and ADA treatment, in order to speed the response and to reduce the risk of anti-TNFα failure, and stopped six months a er starting anti-TNFα therapy.
Disease activity was assessed by the Harvey-Bradshaw Index (HBI) [15] , endoscopic severity was assessed by Simple Endoscopic Score for CD (SES-CD) [16, 17] : to be considered in sustained deep remission for enrolment in this study, participants had to have a HBI score ≤5 points, a SES-CD score 0, and normal values of C-reactive protein (CRP) for at least 6 months. Moreover, patients should have had no changes in their CD medications (IFX or ADA) or any steroid use during the previous 6 months.
Ten patients with active CD (HBI score ≥6 points and SES-CD score ≥2 points) and not taking anti-TNFα treatment served as control group.
Biopsy samples were taken from the intestinal location in which the disease was active before and in remission therea er (active group) or in which the disease was currently active (control group) ( Table I ).
Molecular analysis
Molecular analysis was independently performed by two expert gastrointestinal pathologists (E.I. and F.G.), blinded about the type and the degree of the disease.
e method of detecting mucosal quantitative levels of bFGF, SD1 and TNF-α was a real-time reverse transcriptase PCR (RT-PCR) in biopsy samples from para n samples. We chose this technique because it is simpler and faster than classical immunohistochemistry, and it signi cantly correlates with semiquantitative evaluations obtained by immunohistochemistry [18] . RT-PCR has the ability to reflect the altered pattern of the expression of genes dedicated to the synthesis of a specific molecule and to quantify its transcription levels [18] . erefore, in this study the technique allowed the assessment of the amount of the mRNA codifying for the synthesis of these cytokines in intestinal biopsy samples. e amount was expressed by a numerical value (i.e. the fold change compared to controls, represented by patients undergoing colonic biopsy in absence of endoscopic and histological alteration, e.g., in the case of suspected microscopic or collagenous colitis) [19] . e relative expression of the studied genes levels was calculated using the 2CT method.
Statistics
e collection and analysis of data were performed using MedCalc® Release 11.2.0.0. Chi-square test for categorical variables and Mann-Whitney U test for continuous variables were used. All tests were two-tailed, and the level of signi cance was p=0.05.
Ethics approval
is study was approved by the Institutional Review Board and each subject gave written informed consent.
RESULTS
A total of 28 patients received maintenance therapy and were in deep remission with IFX (11 patients) or ADA (17 patients). The characteristics of the treated patients and controls are summarized in Table I . e characteristics of the CD treated groups are summarized in Table II. When evaluating the cytokine expression, we found that bFGF, SD1 and TNF-α were significantly reduced under J Gastrointestin Liver Dis, September 2014 Vol. 23 No 3: 261-265 treatment with anti-TNFα versus controls (p=0.000; Fig.1 ). Cytokine expression under therapy with IFX and ADA is reported in Fig. 2 ; bFGF and SD1 expression were similar between IFX and ADA patients (p=0.335 and p=0.289, 
DISCUSSION
e achievement of mucosal healing is a critical endpoint in the treatment of CD patients. Achievement of mucosal healing in patients with in ammatory bowel disease carries the prospect of in uencing the natural history of this disease by the prevention of complications, such as the need for surgery or hospitalization. e understanding of basic mechanisms of wound generation and healing is crucial for the improvement of existing and the development of future therapies.
The mechanism by which it occurs has been recently hypothesized. Ierardi et al demonstrated that a decrease of TNF-α, induced by IFX treatment is accompanied by a decrease in both SD1 and bFGF when mucosal healing occurs [20] . A possible explanation is that IFX may down-regulate, via a marked reduction of TNF-α mucosal levels, the bFGF/ SD1 link. is molecular pro le might represent a pathway of mucosal healing. However, the parallel trend of TNF-α, SD1 and bFGF might be just a simultaneous consequence of the control of in ammation. To clarify this last point, a further study on cultured biopsy samples, taken from patients with both CD and ulcerative colitis and incubated in a medium containing comparable amounts of IFX similar to those reached in the serum of treated patients was performed. A er 24 hours, TNF-α, SD1 and bFGF were assayed in tissue homogenates. TNF-α was decreased, while SD1 and bFGF levels were still high when evaluated by both a molecular method and immunohistochemistry [21] . is last nding supports the hypothesis that a mucosal TNF-α reset, induced by biological drugs, is followed by a mucosal restoration in which SD1 modulates the strong reparative bFGF aptitudes.
is mechanism of mucosal restoration has been recently con rmed by De Bruyn et al [22] . e authors found that gene expression of many matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and metalloprotease with thrombospondin motifs [ADAM(TS)s] and growth factor was upregulated in patients with active IBD. A er controlling in ammation with IFX, most gene dysregulations observed at baseline were restored in responders. is con rms that suppression of in ammation results in the arrest of epithelial damage and subsequent mucosal healing [22] .
However, two issues arise from these preliminary analyses: first, what happens when patients are in deep remission (namely under clinical, laboratory and endoscopic remission); second, what happens when we use ADA instead of IFX to treat CD?
With regard to the first question, we found that the framework TNF-α, SD1 and bFGF is signi cantly decreased in CD in deep remission when compared with active disease. In particular, all molecules are simultaneously decreased.
ese results di er from what was previously described in ulcerative colitis, in which TNF-α rapidly decreases under IFX, followed by SD1 and bFGF [21] . e rst and simple hypothesis explaining this result is that the mechanisms involved in the reparative process may be di erent in the two diseases. In fact, we cannot forget that ulcerative colitis is a "mucosal" disease, while CD is a "wall" disease, o en causing brosis. erefore, in CD, but not in ulcerative colitis, the framework TNF-α, SD1 and bFGF may decrease simultaneously under e ect of anti-TNFα drugs. However, a more attractive hypothesis is that the parallel trend of TNF-α, SD1 and bFGF in CD in deep remission might be just a consequence of the control of in ammation. A mucosal TNF-α reset, induced by biological drugs, is followed by a mucosal restoration in which SD1 modulates the strong reparative bFGF aptitudes. Finally, in healed mucosa as in our population, cytokines, adhesion molecules and growth factors resume their normal pattern.
us, the parallel trend of TNF-α, SD1 and bFGF in CD in deep remission might be just a consequence of the optimal control of in ammation.
Regarding the second question, we did not find any di erence in SD1 and bFGF expression between patients under treatment with IFX or ADA, but TNF-α was signi cantly under-expressed in ADA than in IFX patients. It is not easy to explain these surprising results. We know that IFX heals ulcers by the down-regulation of metallo-proteinase [23] and enhancement of tissue inhibitor of metalloproteinase [24] , and that it has distribution and elimination half-lives of 4.3 and 18.5 days, respectively [25] . On the contrary, mean concentrations for patients receiving ADA quickly reach the steady-state, and remain relatively constant during therapy, ranging from 15 to 19 days in relation to the dose administered [26, 27] . Indeed, it is hypothesized that ADA inhibits TNF-α in a deeper way thanks to its stable half-life, due to a 2-week administration. However, there are many variables which could have biased the results, i.e. site of biopsy sampling, time point of biopsy sampling, TNFα antibody trough levels at the time point of biopsy sampling, etc. Hence, this hypothesis needs to be supported by further studies assessing the possible link between ADA levels in blood/colonic mucosa and TNF-α expression in intestinal mucosa.
CONCLUSION
Our results are limited by the small sample number of CD patients enrolled to draw reliable conclusions. However, the present study shows for the rst time that bFGF, SD1 and TNF-α are signi cantly reduced in CD patients in deep remission under treatment with anti-TNFα, likely to be an expression of optimal control of in ammation. e signi cance of the TNF-α under-expression in patients under treatment with ADA with respect to those under treatment with IFX should be elucidated in further studies.
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